598 related articles for article (PubMed ID: 26061646)
21. An oxygen sensitive self-decision making engineered CAR T-cell.
Juillerat A; Marechal A; Filhol JM; Valogne Y; Valton J; Duclert A; Duchateau P; Poirot L
Sci Rep; 2017 Jan; 7():39833. PubMed ID: 28106050
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Antigen Receptor T Cell Therapy in Hematology.
Ataca P; Arslan Ö
Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
[TBL] [Abstract][Full Text] [Related]
23. Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT; Nagato K; Nishimura MI
Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
[TBL] [Abstract][Full Text] [Related]
24. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
[TBL] [Abstract][Full Text] [Related]
25. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
26. Designing chimeric antigen receptors to effectively and safely target tumors.
Jensen MC; Riddell SR
Curr Opin Immunol; 2015 Apr; 33():9-15. PubMed ID: 25621840
[TBL] [Abstract][Full Text] [Related]
27. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
Harris DT; Kranz DM
Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
29. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
Luo C; Wei J; Han W
Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
[TBL] [Abstract][Full Text] [Related]
32. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
33. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
34. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
35. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
36. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
37. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.
Tang XJ; Sun XY; Huang KM; Zhang L; Yang ZS; Zou DD; Wang B; Warnock GL; Dai LJ; Luo J
Oncotarget; 2015 Dec; 6(42):44179-90. PubMed ID: 26496034
[TBL] [Abstract][Full Text] [Related]
39. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
[TBL] [Abstract][Full Text] [Related]
40. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
